Patents by Inventor William Usinger

William Usinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies useful in passive influenza immunization
    Patent number: 10676520
    Abstract: Monoclonal antibodies and fragments thereof that are crossreactive with multiple clades of influenza virus including both Group 1 and Group 2 representatives are disclosed. These antibodies are useful in controlling influenza epidemics and pandemics as well as in providing prophylactic or therapeutic protection against seasonal influenza.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: June 9, 2020
    Assignee: TRELLIS BIOSCIENCE, LLC
    Inventors: Lawrence M. Kauvar, Stote Ellsworth, William Usinger, Krista M. McCutcheon, Minha Park, Bo Chen, Ying-Ping Jiang
  • Antibodies useful in passive influenza immunization
    Patent number: 10654915
    Abstract: Specific monoclonal antibodies and fragments including bispecific antibodies thereof that are crossreactive with multiple clades of influenza virus including both Group 1 and Group 2 representatives are disclosed. These antibodies are useful in controlling influenza epidemics and pandemics as well as in providing prophylactic or therapeutic protection against seasonal influenza.
    Type: Grant
    Filed: December 5, 2012
    Date of Patent: May 19, 2020
    Assignee: TRELLIS BIOSCIENCE, LLC
    Inventors: Lawrence M. Kauvar, Stote Ellsworth, William Usinger, Krista Maureen McCutcheon, Minha Park
  • High affinity human antibodies to human cytomegalovirus (CMV) gB protein
    Patent number: 10030069
    Abstract: Recombinant monoclonal antibodies to human cytomegalovirus (CMV) gB protein are described. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: July 24, 2018
    Assignee: Trellis Bioscience, LLC
    Inventors: Lawrence M. Kauvar, Stote Ellsworth, William Usinger, Krista Maureen McCutcheon, Ying-Ping Jiang, Fen Zhang, Bo Chen, Gizette Sperinde, Minha Park, Orit Foord
  • HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN CYTOMEGALOVIRUS (CMV) GB PROTEIN
    Publication number: 20170204165
    Abstract: Recombinant monoclonal antibodies to human cytomegalovirus (CMV) gB protein are described. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.
    Type: Application
    Filed: March 20, 2017
    Publication date: July 20, 2017
    Applicant: Trellis Bioscience, LLC
    Inventors: Lawrence M. KAUVAR, Stote ELLSWORTH, William USINGER, Krista Maureen MCCUTCHEON, Ying-Ping JIANG, Fen ZHANG, Bo CHEN, Gizette SPERINDE, Minha PARK, Orit FOORD
  • High affinity human antibodies to human cytomegalovirus (CMV) GB protein
    Patent number: 9688744
    Abstract: Recombinant monoclonal antibodies to human cytomegalovirus (CMV) gB protein are described. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: June 27, 2017
    Assignee: Trellis Bioscience, LLC
    Inventors: Lawrence M. Kauvar, Stote Ellsworth, William Usinger, Krista Maureen McCutcheon, Ying-Ping Jiang, Fen Zhang, Bo Chen, Gizette Sperinde, Minha Park, Orit Foord
  • HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN CYTOMEGALOVIRUS (CMV) GB PROTEIN
    Publication number: 20150252099
    Abstract: Recombinant monoclonal antibodies to human cytomegalovirus (CMV) gB protein are described. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.
    Type: Application
    Filed: April 27, 2015
    Publication date: September 10, 2015
    Inventors: Lawrence M. KAUVAR, Stote ELLSWORTH, William USINGER, Krista Maureen MCCUTCHEON, Ying-Ping JIANG, Fen ZHANG, Bo CHEN, Gizette SPERINDE, Minha PARK, Orit FOORD
  • High affinity human antibodies to human cytomegalovirus (CMV) gB protein
    Patent number: 9017668
    Abstract: Antibodies to human Cytomegalovirus (CMV) gB protein have been isolated from human B cells. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: April 28, 2015
    Assignee: Trellis Bioscience, LLC
    Inventors: Lawrence M. Kauvar, Stote Ellsworth, William Usinger, Krista Maureen McCutcheon, Ying-Ping Jiang, Fen Zhang, Bo Chen, Gizette Sperinde, Minha Park, Orit Foord
  • ANTIBODIES USEFUL IN PASSIVE INFLUENZA IMMUNIZATION
    Publication number: 20140322210
    Abstract: Specific monoclonal antibodies and fragments including bispecific antibodies thereof that are crossreactive with multiple clades of influenza virus including both Group 1 and Group 2 representatives are disclosed. These antibodies are useful in controlling influenza epidemics and pandemics as well as in providing prophylactic or therapeutic protection against seasonal influenza.
    Type: Application
    Filed: December 5, 2012
    Publication date: October 30, 2014
    Inventors: Lawrence M. Kauvar, Stote Ellsworth, William Usinger, Krista Maureen McCutcheon, Minha Park
  • HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN CYTOMEGALOVIRUS (CMV) GB PROTEIN
    Publication number: 20120020980
    Abstract: Antibodies to human Cytomegalovirus (CMV) gB protein have been isolated from human B cells. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.
    Type: Application
    Filed: June 16, 2011
    Publication date: January 26, 2012
    Applicant: TRELLIS BIOSCIENCE, INC.
    Inventors: LAWRENCE M. KAUVAR, STOTE ELLSWORTH, WILLIAM USINGER, KRISTA MAUREEN MCCUTCHEON, YING-PING JIANG, FEN ZHANG, BO CHEN, GIZETTE SPERINDE, MINHA PARK, ORIT FOORD
  • ANTIBODIES USEFUL IN PASSIVE INFLUENZA IMMUNIZATION
    Publication number: 20120020971
    Abstract: Monoclonal antibodies and fragments thereof that are crossreactive with multiple clades of influenza virus including both Group 1 and Group 2 representatives are disclosed. These antibodies are useful in controlling influenza epidemics and pandemics as well as in providing prophylactic or therapeutic protection against seasonal influenza.
    Type: Application
    Filed: June 17, 2011
    Publication date: January 26, 2012
    Applicant: Trellis Bioscience, Inc.
    Inventors: Lawrence M. KAUVAR, Stote Ellsworth, William Usinger, Krista M. McCutcheon, Minha Park, Bo Chen, Ying-Ping Jiang
  • Methods of assaying connective tissue growth factor
    Publication number: 20070020692
    Abstract: The present invention relates to methods of detection and quantitation of connective tissue growth factor (CTGF), and diagnosis and detection of various CTGF-associated diseases and disorders.
    Type: Application
    Filed: September 22, 2006
    Publication date: January 25, 2007
    Applicant: FibroGen, Inc.
    Inventors: Stephen Weitz, William Usinger
  • Diabetic nephropathy therapies
    Publication number: 20050214294
    Abstract: The present invention relates to methods and compounds for treating specific early stage aspects and late stage aspects of diabetic nephropathy. Methods and compounds for treating various physiological features associated with early stage and with late stage diabetic nephropathy are also provided.
    Type: Application
    Filed: February 11, 2005
    Publication date: September 29, 2005
    Inventors: Allan Flyvbjerg, Guangjie Guo, David Liu, Thomas Neff, Noelynn Oliver, William Usinger, Qingjian Wang
  • Cytophaga-derived immunopotentiator
    Patent number: 4978622
    Abstract: Substantially pigment-free gliding bacteria adjuvant (GBA) is isolated from medium in which Cytophaga strain GB-2 has been cultured by extraction with acetone to remove pigment, enzymatic digestion and filtration to remove residual protein and nucleic acids, and affinity chromatography to remove residual lipopolysaccharide. This pure form of GBA shows unexpectedly high specific immunopotentiating activity relative to crude GBA.
    Type: Grant
    Filed: September 1, 1989
    Date of Patent: December 18, 1990
    Assignee: Regents of the University of California
    Inventors: Robert Mishell, William Usinger